Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Sell
37
ARKG Quote, Financials, Valuation and Earnings
Last price:
$23.46
Seasonality move
:
1.68%
Day range:
$22.61 - $23.70
52-week range:
$21.56 - $31.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.4M
Avg. volume:
3.7M
1-year change:
-17.51%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
$23.46 | -- | -- | -- | $0.00 | 0% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$61.49 | -- | -- | -- | $0.00 | 0% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$169.21 | -- | -- | -- | $1.17 | 0.69% | -- |
|
IBB
iShares Biotechnology ETF
|
$134.19 | -- | -- | -- | $0.06 | 0.29% | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
$39.42 | -- | -- | -- | $0.03 | 0.07% | -- |
|
XBI
SPDR S&P Biotech ETF
|
$87.13 | -- | -- | -- | $0.00 | 0.15% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | 2.857 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 1.217 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 1.243 | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | 1.306 | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | 1.594 | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | 1.588 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
ARK Genomic Revolution ETF vs. Competitors
-
Which has Higher Returns ARKG or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About ARKG or BBP?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is ARKG or BBP More Risky?
ARK Genomic Revolution ETF has a beta of 1.699, which suggesting that the stock is 69.933% more volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.678, suggesting its less volatile than the S&P 500 by 32.175%.
-
Which is a Better Dividend Stock ARKG or BBP?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or BBP?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns ARKG or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About ARKG or FBT?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe ARK Genomic Revolution ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is ARKG or FBT More Risky?
ARK Genomic Revolution ETF has a beta of 1.699, which suggesting that the stock is 69.933% more volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.732, suggesting its less volatile than the S&P 500 by 26.822%.
-
Which is a Better Dividend Stock ARKG or FBT?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0.69% to investors and pays a quarterly dividend of $1.17 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or FBT?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns ARKG or IBB?
iShares Biotechnology ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat iShares Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- IBBiShares Biotechnology ETF-- -- -- -
What do Analysts Say About ARKG or IBB?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than iShares Biotechnology ETF, analysts believe ARK Genomic Revolution ETF is more attractive than iShares Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 IBBiShares Biotechnology ETF0 0 0 -
Is ARKG or IBB More Risky?
ARK Genomic Revolution ETF has a beta of 1.699, which suggesting that the stock is 69.933% more volatile than S&P 500. In comparison iShares Biotechnology ETF has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.628%.
-
Which is a Better Dividend Stock ARKG or IBB?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iShares Biotechnology ETF offers a yield of 0.29% to investors and pays a quarterly dividend of $0.06 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. iShares Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or IBB?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than iShares Biotechnology ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than iShares Biotechnology ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while iShares Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for iShares Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- IBBiShares Biotechnology ETF-- -- -- --
-
Which has Higher Returns ARKG or PTH?
Invesco Dorsey Wright Healthcare Momentum ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Invesco Dorsey Wright Healthcare Momentum ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- PTHInvesco Dorsey Wright Healthcare Momentum ETF-- -- -- -
What do Analysts Say About ARKG or PTH?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Dorsey Wright Healthcare Momentum ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Invesco Dorsey Wright Healthcare Momentum ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Invesco Dorsey Wright Healthcare Momentum ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 PTHInvesco Dorsey Wright Healthcare Momentum ETF0 0 0 -
Is ARKG or PTH More Risky?
ARK Genomic Revolution ETF has a beta of 1.699, which suggesting that the stock is 69.933% more volatile than S&P 500. In comparison Invesco Dorsey Wright Healthcare Momentum ETF has a beta of 0.902, suggesting its less volatile than the S&P 500 by 9.824%.
-
Which is a Better Dividend Stock ARKG or PTH?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Dorsey Wright Healthcare Momentum ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Invesco Dorsey Wright Healthcare Momentum ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or PTH?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Invesco Dorsey Wright Healthcare Momentum ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Invesco Dorsey Wright Healthcare Momentum ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Invesco Dorsey Wright Healthcare Momentum ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Invesco Dorsey Wright Healthcare Momentum ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- PTHInvesco Dorsey Wright Healthcare Momentum ETF-- -- -- --
-
Which has Higher Returns ARKG or XBI?
SPDR S&P Biotech ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- XBISPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About ARKG or XBI?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than SPDR S&P Biotech ETF, analysts believe ARK Genomic Revolution ETF is more attractive than SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 XBISPDR S&P Biotech ETF0 0 0 -
Is ARKG or XBI More Risky?
ARK Genomic Revolution ETF has a beta of 1.699, which suggesting that the stock is 69.933% more volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.824%.
-
Which is a Better Dividend Stock ARKG or XBI?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Biotech ETF offers a yield of 0.15% to investors and pays a quarterly dividend of $0.00 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or XBI?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- XBISPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
49
SMTC alert for Mar 17
Semtech [SMTC] is down 0.49% over the past day.
Buy
62
PLPC alert for Mar 17
Preformed Line Products [PLPC] is up 3.8% over the past day.
Sell
50
NUTX alert for Mar 17
Nutex Health [NUTX] is up 4.82% over the past day.
